Website beoordeling medincell.com
Medincell - Impacting Global Health with Purposeful Innovation
Gegenereerd op Mei 04 2026 08:46 AM
Oude statistieken? UPDATE !
De score is 54/100
SEO Content
Title
Medincell - Impacting Global Health with Purposeful Innovation
Lengte : 62
Perfect, uw title tag bevat tussen de 10 en 70 karakters.
Description
MedinCell creates better medicine for all through innovative long‑acting therapies that help improve global health.
Lengte : 115
Perfect, uw meta description bevat tussen de 70 en 160 karakters.
Keywords
Erg slecht. We hebben geen meta keywords gevonden in uw website. Gebruik deze gratis online meta tags generator om keywords te genereren.
Og Meta Properties
Goed, uw page maakt gebruik van Og Properties.
| Property | Content |
|---|---|
| url | https://www.medincell.com/ |
| site_name | Medincell |
| locale | en_US |
| locale:alternate | fr_FR |
| type | website |
| title | Medincell - Impacting Global Health with Purposeful Innovation |
| description | Join Medincell on a journey to transform global health with innovative therapies. |
| image | https://www.medincell.com/wp-content/uploads/2026/02/Open_graph.jpg |
| image:secure_url | https://www.medincell.com/wp-content/uploads/2026/02/Open_graph.jpg |
| image:width | 1640 |
| image:height | 856 |
| image:alt | Logo de Medincell en bleu |
Headings
| H1 | H2 | H3 | H4 | H5 | H6 |
| 1 | 9 | 5 | 25 | 0 | 0 |
- [H1] Impacting Global Health with Purposeful Innovation
- [H2] Latest news & events
- [H2] Improving health worldwide through new therapeutic options
- [H2] Key figures
- [H2] Products & R&D pipeline
- [H2] mdc-TJK
- [H2] mdc-CWM
- [H2] Join the team
- [H2] Corporate presentation
- [H2] Get in touch
- [H3] Products on market
- [H3] UZEDY®
- [H3] Programs in clinical phase 3
- [H3] mdc-TJK
- [H3] mdc-CWM
- [H4] UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year
- [H4] Degroof Petercam Initiates Medincell’s Coverage with a “Buy” Recommendation
- [H4] Leerink Partners Initiates Medincell’s Coverage with a “Outperform” Recommendation
- [H4] Medincell to Host an online R&D Day on Tuesday, May 12, 2026
- [H4] 1
- [H4] 2
- [H4] 140
- [H4] 25
- [H4] U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
- [H4] UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) ; OLANZAPINE LAI: EU Submission Expected in Q2 2026
- [H4] Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
- [H4] UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025
- [H4] New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
- [H4] Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
- [H4] UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
- [H4] UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025
- [H4] Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI
- [H4] Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia
- [H4] Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM
- [H4] Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
- [H4] MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
- [H4] MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
- [H4] MedinCell: mdc-CWM clinical phase 3 will start in 2021
- [H4] MedinCell provides a portfolio update for J.P. Morgan Healthcare Conference 2020
- [H4] MedinCell announces that mdc-CWM progresses as planned
Afbeeldingen
We vonden 8 afbeeldingen in de pagina.
4 alt attributen ontbreken. Voeg alternatieve text toe zodat zoekmachines beter kunnen beoordelen wat het onderwerp van de afbeeldingen is.
Text/HTML Ratio
Ratio : 1%
De ratio van text tot HTML code is below 15 procent, dit betekent dat uw pagina waarschijnlijk meer tekst nodig heeft.
Flash
Perfect, geen Flash content gevonden in uw website.
Iframe
Jammer, u heeft Iframes in uw website, dit betekent dat deze content niet kan worden geïndexeerd.
SEO Links
Herschreven URL
Perfect. Uw links zien er vriendelijk uit!
Underscores in de URLs
Perfect! Geen underscores gevonden in uw URLs.
In-page links
We vonden een totaal van 30 links inclusie 1 link(s) naar bestanden
| Ankertekst | Type | samenstelling |
|---|---|---|
| Skip to main content | Intern | doFollow |
| Access Event | Intern | doFollow |
| Home | Intern | doFollow |
| See our R&D pipeline | Intern | doFollow |
| - | Intern | doFollow |
| See our open positions | Intern | doFollow |
| I have read and accept the privacy policy | Intern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| - | Extern | doFollow |
| Home | Intern | doFollow |
| About Us | Intern | doFollow |
| Impact company | Intern | doFollow |
| Our people | Intern | doFollow |
| Leadership team | Intern | doFollow |
| UZEDY® | Intern | doFollow |
| R&D Pipeline | Intern | doFollow |
| BEPO® Technology | Intern | doFollow |
| Publications | Intern | doFollow |
| Our commitments | Intern | doFollow |
| Code and policies | Intern | doFollow |
| 2025 ESG Report | Intern | doFollow |
| Our vision & our values | Intern | doFollow |
| Work environment & benefits | Intern | doFollow |
| News | Intern | doFollow |
| Events | Intern | doFollow |
| Overview | Intern | doFollow |
| Regulated information | Intern | doFollow |
| General Meeting | Intern | doFollow |
| Contact | Intern | doFollow |
SEO Keywords
Keywords Cloud
news search events vision team medincell values benefits information environment
Keywords Consistentie
| Keyword | Content | Title | Keywords | Description | Headings |
|---|---|---|---|---|---|
| news | 4 |  |
|
|
 |
| information | 4 | |
|
|
|
| events | 4 | |
|
|
|
| medincell | 3 | |
|
|
|
| vision | 3 | |
|
|
|
Bruikbaarheid
Url
Domein : medincell.com
Lengte : 13
Favicon
Goed, uw website heeft een favicon.
Printbaarheid
Jammer. We vonden geen Print-Vriendelijke CSS.
Taal
Goed. Uw ingestelde taal is en.
Dublin Core
Geweldig. Deze pagina maakt gebruik van Dublin Core.
Document
Doctype
HTML 5
Encoding
Perfect. Uw ingestelde Charset is UTF-8.
W3C Validiteit
Fouten : 0
Waarschuwingen : 0
E-mail Privacy
Geweldig er is geen e-mail adres gevonden als platte tekst!
Niet ondersteunde HTML
Geweldig! We hebben geen niet meer ondersteunde HTMl tags gevonden in uw HTML.
Speed Tips
|
Geweldig, uw website heeft geen tabellen in een tabel. |
|
Jammer, uw website maakt gebruik van inline styles. |
|
Jammer, uw website heeft teveel CSS bestanden (meer dan 4). |
|
Jammer, uw website heeft teveel JS bestanden (meer dan 6). |
|
Perfect, uw website haalt voordeel uit gzip. |
Mobile
Mobile Optimization
|
Apple Icon |
|
Meta Viewport Tag |
|
Flash content |
Optimalisatie
XML Sitemap
Geweldig, uw website heeft een XML sitemap.
| https://www.medincell.com/sitemaps.xml |
Robots.txt
https://medincell.com/robots.txt
Geweldig uw website heeft een robots.txt bestand.
Analytics
Ontbrekend
We hadden niet op te sporen van een analytics tool op deze website geplaatst.
Web Analytics laat u toe de bezoekersactiviteit op uw website te meten. U zou minstens 1 Analytics tool geïnstalleerd moeten hebben en een extra tool voor de bevestiging van de resultaten.
PageSpeed Insights
Device
Categorieën
Free SEO Testing Tool
Website review is een gratis tool waarmee u eenvoudig uw website kunt analyseren